logo

For the Inventor, By the Inventor

Paris, France

Roussel Uclaf


USPTO Granted Patents = 854


Trademarks = 6

Forward Citations = 6,662

Loading Chart...
Loading Chart...

474 inventors (with patents filed for the assignee):

goldMedal Jean Tessier (100 out of 104 patents)

silverMedal Jean-Pierre Demoute (89 out of 91 patents)

bronzeMedal Jacques Martel (80 out of 82 patents)

4.  Francois Clemence (71 out of 75 patents)

5.  Lucien Nedelec (69 out of 72 patents)

6.  Jean Buendia (51 out of 55 patents)

7.  Odile Le Martret (47 out of 50 patents)

8.  Daniel Philibert (46 out of 55 patents)

9.  Roger Deraedt (39 out of 40 patents)

10.  Michel Fortin (37 out of 43 patents)

11.  Andre Teche (37 out of 37 patents)

12.  Michel Vivat (35 out of 40 patents)

13.  Fernando Barzaghi (34 out of 34 patents)

14.  Claude Dumont (32 out of 32 patents)

15.  Rene Heymes (31 out of 38 patents)


Core Competencies:
Cephalosporins
Erythromycins
Steroids
Imidazolidines
Phospholipids
Biological Control Agents
Nucleotide Sequences
Antiandrogenic Activity
Vasoconstriction Inhibition
Granule Preparation
Male Fertility Control

854 patents:

1. 5985292 - Active phospholipids as a vector for active molecules (1999-11-16),
2. 5965417 - Arabidepsi thaliana proteins having (1999-10-12),
3. 5917126 - Saccharose phosphate synthetase (SPS), a preparation method and CDNA (1999-06-29),
4. 5892028 - 17, 20-epoxy steroids (1999-04-06),
5. 5883248 - Cephalosporins (1999-03-16),
6. 5874076 - Administration of non-glycosylated, recombinant human IL.sub.2 in (1999-02-23),
7. 5869283 - Expression cassette operable in a recombinant host (1999-02-09),
8. 5856509 - Derivatives of imidazole, their preparation process, the new (1999-01-05),
9. 5847124 - Hydrated forms of zilpatherol hydrochloride (1998-12-08),
10. 5834452 - 1- or 6-hydroxylated steroids (1998-11-10),
11. 5830758 - Isolated V.beta. TCR antibodies (1998-11-03),
12. 5827887 - Biphenyl compounds (1998-10-27),
13. 5817674 - Quinoline compounds (1998-10-06),
14. 5817511 - Nucleotide sequence coding for variable regions of the .alpha. chains of (1998-10-06),
15. 5811445 - Method of preventing abnormal stimulation of AT.sub.1 and AT.sub.2 (1998-09-22),
Company Overview
Roussel Uclaf is a prominent player in the pharmaceutical industry, headquartered in Paris, France. The company specializes in the development and manufacturing of a diverse range of pharmaceutical compounds, with a strong focus on cephalosporins, erythromycins, and steroids. Roussel Uclaf is also engaged in advanced research in areas such as imidazolidines, phospholipids, and biological control agents, contributing to innovative solutions in healthcare. Its expertise extends to nucleotide sequences and antiandrogenic activity, positioning the company at the forefront of pharmaceutical advancements.
Profile summary synthesized from public USPTO records and patent filings.

logo

Company Badge

USPTO Data Jan 1 1976 - Oct 13 2026

854 Patents

#15 in Paris

#30 in France

#1,174 in the World

Paris, FR
Paris, France

Roussel Uclaf

Forward Citations = 6,662

474 inventors:

goldMedal Jean Tessier (100 out of 104 patents)

silverMedal Jean-Pierre Demoute (89 out of 91 patents)

bronzeMedal Jacques Martel (80 out of 82 patents)

4.  Francois Clemence (71 out of 75 patents)

5.  Lucien Nedelec (69 out of 72 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Roussel Uclaf. Retrieved from https://idiyas.com/company/roussel-uclaf

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…